M&A · Healthcare · Pharmaceutical Preparations
Jazz Pharmaceuticals plc to acquire Chimerix Inc
Announced Mar 5, 2025 · Closed Apr 21, 2025
Deal value$935MEV $745M
Premium72.0%To unaffected price
EV / Adj. EBITDA—
ConsiderationAll cash$8.55 per share
Transaction
- Acquirer
- Jazz Pharmaceuticals plc (JAZZ)
- Target
- Chimerix Inc (CMRX)
- Buyer type
- Strategic
- Offer price per share
- $8.55
- Enterprise value
- $745M
- Status
- Closed Apr 21, 2025
Deal protections
- Break fee (target pays)
- $35.0M · 3.7%
- Reverse fee (buyer pays)
- —
- Go-shop
- No-shop
- Financing
- —
Advisors
- To the acquirer
- Guggenheim
- To the target
- Centerview
Sector context · Healthcare
- Comparable deals
- 93 in the prior 24 months
- Premium
- 72.0% vs. 65.0% sector median
- EV / Adj. EBITDA
- Sector median 13.8x
- Break fee
- 3.7% vs. 3.4% sector median
Timeline
- AnnouncedMar 5, 2025
- Tender offerMar 21, 2025
- ClosedApr 21, 2025